Patents by Inventor Ho Yin Lo
Ho Yin Lo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240050429Abstract: Disclosed are a pazopanib pharmaceutical composition, an injection and a preparation method and the use thereof. The pharmaceutical composition comprises the following components: pazopanib, a cyclodextrin solubilizer and a solvent, wherein the mass ratio of the pazopanib to the cyclodextrin solubilizer is 1:(13 to 100), and based on 1 mL of the pharmaceutical composition, the concentration of the cyclodextrin solubilizer in the pharmaceutical composition is 6 to 330 mg/mL. The pharmaceutical composition prepared in the present disclosure can be used for treating diseases such as acute lung injury, pulmonary fibrosis and acute respiratory distress syndrome, and the therapeutic purpose can be achieved by using only a small amount of pazopanib; and the pharmaceutical composition has a high bioavailability, a high stability and a low impurity content, and there is no occurrence of drug accumulation phenomenon.Type: ApplicationFiled: August 10, 2022Publication date: February 15, 2024Inventors: Xiaofeng LI, Ho Yin Lo
-
Patent number: 11731985Abstract: The present invention relates to the field of anti-cancer compounds. More particularly, the invention relates to a family of benzothiazolyl urea or thiorurea compound useful as such agents. The present invention also relates to methods for treating cancers using these compounds.Type: GrantFiled: May 8, 2019Date of Patent: August 22, 2023Assignee: Hb Therapeutics Inc.Inventors: Anita Bellail, Chunhai Hao, Ho Yin Lo
-
Publication number: 20230181582Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with viral infections, such as those due to coronaviruses that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries often associated with these infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/AP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof, The present invention also provides devices for administering the compositions.Type: ApplicationFiled: May 20, 2021Publication date: June 15, 2023Applicants: Qx Therapeutics Inc., Yale UniversityInventors: Dianqing Wu, Ho Yin Lo
-
Patent number: 11497747Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.Type: GrantFiled: March 17, 2022Date of Patent: November 15, 2022Assignees: Qx Therapeutics Inc., Yale UniversityInventors: Dianqing Wu, Ho Yin Lo
-
Publication number: 20220202816Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.Type: ApplicationFiled: March 17, 2022Publication date: June 30, 2022Applicants: Qx Therapeutics Inc., Yale UniversityInventors: Dianqing Wu, Ho Yin Lo
-
Patent number: 11304947Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.Type: GrantFiled: May 20, 2021Date of Patent: April 19, 2022Assignees: Qx Therapeutics Inc., Yale UniversityInventors: Dianqing Wu, Ho Yin Lo
-
Publication number: 20210361650Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.Type: ApplicationFiled: May 20, 2021Publication date: November 25, 2021Applicants: Qx Therapeutics Inc., Yale UniversityInventors: Dianqing Wu, Ho Yin Lo
-
Publication number: 20210299117Abstract: Smad3 inhibitor compounds, specifically a compound of Formula 1 or Formula 2, or a pharmaceutically acceptable salt thereof, and its use in treating or preventing cell proliferation or cancer in a subject are provided.Type: ApplicationFiled: August 6, 2019Publication date: September 30, 2021Inventor: Ho Yin LO
-
Publication number: 20210115064Abstract: The present invention relates to the field of anti-cancer compounds. More particularly, the invention relates to a family of benzothiazolyi urea or thiorurea compound useful as such agents. The present invention also relates to methods for treating cancers using these compounds.Type: ApplicationFiled: May 8, 2019Publication date: April 22, 2021Applicant: Hb Therapeutics Inc.Inventors: Anita Bellail, Chunhai Hao, Ho Yin Lo
-
Patent number: 9174980Abstract: The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R7, A and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: January 29, 2013Date of Patent: November 3, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Alessandra Bartolozzi, Zhidong Chen, Jonathon Alan Dines, Ho Yin Lo, Pui Leng Loke, Alan Olague, Doris Riether, Heather Tye, Lifen Wu, Renee M. Zindell
-
Patent number: 9150556Abstract: Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.Type: GrantFiled: May 15, 2008Date of Patent: October 6, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Asitha Abeywardane, Brian Nicholas Cook, Stephane De Lombaert, Michel Jose Emmanuel, Xin Guo, Ming-Hong Hao, Jin Mi Kim, Ho Yin Lo, Chuk Chui Man, Tina Marie Morwick, Peter Allen Nemoto, Kevin Chungeng Qian, Hidenori Takahashi, Steven John Taylor
-
Patent number: 9062056Abstract: Disclosed are small molecule inhibitors of the formula (I): and the pharmaceutical compositions thereof and processes of making the same. The compounds are useful in treating various diseases and conditions involving chymase.Type: GrantFiled: August 25, 2009Date of Patent: June 23, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Michel Jose Emmanuel, Xin Guo, Jin Mi Kim, Ho Yin Lo, Peter Allen Nemoto, Kevin Chungeng Qian
-
Patent number: 8829200Abstract: The present invention relates to compounds of formula (IA) and (IB): and pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: October 26, 2011Date of Patent: September 9, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Zhidong Chen, Stephane De Lombaert, Jonathon Alan Dines, Weimin Liu, Ho Yin Lo, Pui Leng Loke
-
Patent number: 8772304Abstract: The present invention relates to compounds of formula (IA), (IB) and (IC): and pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: October 26, 2011Date of Patent: July 8, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Stephane De Lombaert, Weimin Liu, Ho Yin Lo, Peter Allen Nemoto
-
Patent number: 8658661Abstract: The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: August 12, 2011Date of Patent: February 25, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Alessandra Bartolozzi, Todd Bosanac, Zhidong Chen, Stephane De Lombaert, John D. Huber, Ho Yin Lo, Pui Leng Loke, Weimin Liu, Tina Marie Morwick, Alan Olague, Doris Riether, Heather Tye, Lifen Wu, Renee M. Zindell
-
Patent number: 8618300Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salt thereof, wherein X1 to X4, R1 to R4, A, B, D and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: August 25, 2009Date of Patent: December 31, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Todd Bosanac, Stephane De Lombaert, Ho Yin Lo, Peter Allen Nemoto, Alan Olague
-
Patent number: 8580825Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: September 20, 2011Date of Patent: November 12, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Alessandra Bartolozzi, Todd Bosanac, Zhidong Chen, Stephane De Lombaert, John D. Huber, Weimin Liu, Ho Yin Lo, Pui Leng Loke, Doris Riether, Heather Tye, Lifen Wu, Renee M. Zindell
-
Patent number: 8580829Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: August 23, 2011Date of Patent: November 12, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Alessandra Bartolozzi, Todd Bosanac, Zhidong Chen, Stephane De Lombaert, Jonathon Alan Dines, John D. Huber, Weimin Liu, Ho Yin Lo, Pui Leng Loke, Tina Marie Morwick, Peter Allen Nemoto, Alan Olague, Doris Riether, Heather Tye, Lifen Wu, Renee M. Zindell
-
Publication number: 20130196967Abstract: The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R7, A and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: ApplicationFiled: January 29, 2013Publication date: August 1, 2013Inventors: Alessandra BARTOLOZZI, Zhidong CHEN, Jonathon Alan DINES, Ho Yin LO, Pui Leng LOKE, Alan OLAGUE, Doris RIETHER, Heather TYE, Lifen WU, Renee M. ZINDELL
-
Patent number: 8420655Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salt thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: December 1, 2010Date of Patent: April 16, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Zhidong Chen, Ming-Hong Hao, Weimin Liu, Ho-Yin Lo, Pui Leng Loke, Chuk Chui Man, Tina Marie Morwick, Peter Allen Nemoto, Hidenori Takahashi, Heather Tye, Lifen Wu